Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

We’re encouraged to drink more water because ‘it’s good for us.’ Now, a new study has tested that claim, examining the evidence from previous studies to see whether increasing the amount of water you ...

Dr Dakalo Muavha, South Africa's first black urogynaecologist, is revolutionising women’s health with advanced care and compassion.

Medication remains a common first-line treatment, with several types available depending on the specific condition and symptoms. Anticholinergic medications help reduce bladder spasms and decrease ...

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...

Other prescription treatment options include Botox (onabotulinumtoxinA), beta-3 adrenergic ... Studies have shown that topical application of low-dose estrogen may help postmenopausal women with ...